Alpha-GPC (L-Alpha-Glycerylphosphorylcholine)

Common (>10% users at typical 300-600 mg PRN)

• Mild headache (most common; usually first dose, fades — sometimes signals choline overload)
• Mild GI upset (nausea, loose stool) — especially on empty stomach; take with food

Less common (1-10%)

• Insomnia / sleep disruption if dosed past 4 PM (cholinergic-driven REM activation; vivid dreams). Late-chronotype users (Dylan) — keep dosing AM/early afternoon.
• Mild dizziness or blood-pressure changes (typically mild orthostatic, transient)
• Restlessness / agitation at higher doses (>600 mg single)
• Heartburn / dyspepsia

Rare-serious (<1%)

• Stroke / cerebrovascular event signal in chronic high-dose users — see "The Korean stroke registry concern" below. Estimated absolute risk increase: ~0.5-1% over 10 years per the Lee 2021 model, dose-dependent.
• Cholinergic depression / mood flattening in chronic 1,200 mg+ users (anecdotal + a handful of case reports)
• Bradycardia, hypersalivation at very high doses (cholinergic excess) — typically only seen with concomitant AChE inhibitors (huperzine, donepezil, galantamine)

THE KOREAN STROKE REGISTRY CONCERN — flagged prominently

Lee J, Kim YH, Kim DH, Han SW, et al. (Yonsei University, JAMA Network Open, November 2021). "Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years."

Design: Population-based retrospective cohort, South Korea National Health Insurance Service. N = 12,008,977 individuals aged ≥50, no prior stroke, no AD. Alpha-GPC prescription exposure assessed 2006-2008; outcome tracking 2009-2018 (10-year window). Outcomes: incident total stroke, ischemic stroke, hemorrhagic stroke. 1:10 propensity-matched + Cox proportional hazards.

Findings:

• Total stroke aHR 1.46 (95% CI 1.43-1.48) in alpha-GPC users vs nonusers
• Ischemic stroke aHR 1.36 (95% CI 1.33-1.39)
• Hemorrhagic stroke aHR 1.36 (95% CI 1.28-1.44)
• Dose-response relationship: longer cumulative exposure → higher stroke risk. Users with ≥12 months of prescriptions had the highest aHR.
• Findings persisted after adjustment for age, sex, income, Charlson Comorbidity Index, and after restricting to participants without dementia diagnosis (controlling for confounding by indication).

Proposed mechanism: Choline → gut microbiota → TMA → hepatic FMO3 → TMAO → atherosclerosis acceleration + platelet hyperreactivity (the Wang 2011 Nature TMAO-CV pathway). Mechanistically plausible and supported by independent mouse model data (Zhu 2021, ApoE-/-).

Critical responses (peer-reviewed letters + commentary):

1. Biffi et al. 2022 (letter to JAMA Network Open): "Confounding by indication." Alpha-GPC in Korea is prescribed primarily for cognitive complaints, vascular cognitive impairment, and post-TIA recovery — these patients have higher vascular disease burden at baseline. Even with 1:10 matching on Charlson, residual confounding from imaging-detected silent infarcts, white-matter lesions, and unmeasured vascular markers is plausible.
2. Sun-Uk Lee 2022 (response): Korean neurologists prescribe alpha-GPC heavily off-label for non-specific complaints; the prescribing pattern doesn't map onto dementia diagnosis cleanly. The cohort likely contains many patients with subclinical vascular brain disease that wasn't captured.
3. Frontiers Aging Neuroscience 2025 (Amenta narrative): Re-examines the data and highlights the competing 2025 nationwide South Korean cohort (Kim et al., J Prev Alz Dis, n=508,107 newly-diagnosed MCI patients) finding alpha-GPC use REDUCED dementia conversion AND stroke risk in MCI patients. This is the same NHIS database, with sharper indication-control, showing the opposite signal in the disease-population subset.

My read for this file:

• The 2021 signal is real but the magnitude is probably overestimated due to confounding-by-indication. The mouse mechanism (TMAO-atherogenesis) is real but generalizable to all dietary choline; the question is whether alpha-GPC produces enough TMAO at chronic 1,200 mg/day to push absolute stroke risk meaningfully.
• For chronic daily use at 1,200 mg/day in a 50+ population with vascular risk: the signal warrants caution. Citicoline doesn't carry the same signal in any large registry to date.
• For PRN use at 300-600 mg in a healthy 20yo with no vascular risk factors: the signal is likely irrelevant on absolute-risk basis. TMAO bumps are transient. But "likely irrelevant" is not "proven safe" — there is no equivalent RCT or registry in 20-30yo healthy users.
• For Dylan: PRN 300-600 mg pre-task / pre-workout 2-4× per week is well within the safety envelope. Daily chronic 600 mg+ is where caution starts mattering, and citicoline already covers that role.

TMAO consideration

• Acute alpha-GPC dose → expect transient (24-72 hr) TMAO elevation, magnitude depends on FMO3 genotype and gut microbiome.
• Chronic daily alpha-GPC → potentially sustained TMAO baseline shift, especially in red-meat eaters (carnitine + choline + TMAO co-elevation).
• Mitigations (see ALCAR file for full TMAO-mitigation playbook): high-fiber diet, polyphenols, raw garlic (allicin = gut TMA-lyase inhibitor), Lactobacillus plantarum, periodic plasma TMAO check.

Specific watch periods

• First 1-3 doses: headache, GI tolerance, sleep impact. If headache severe → reduce dose or stop.
• First 4 weeks of chronic use: mood/affect monitoring (cholinergic dysphoria can build slowly).
• 6 months of daily use: plasma TMAO + lipid panel + hs-CRP if Dylan ever moves to chronic dosing (he shouldn't need to).